IRIS
CONTEDUCA, VINCENZA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.204
AS - Asia 2.129
NA - Nord America 1.593
SA - Sud America 1.026
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 7.010
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.517
IE - Irlanda 1.082
SG - Singapore 897
BR - Brasile 850
HK - Hong Kong 411
VN - Vietnam 396
RU - Federazione Russa 361
SE - Svezia 268
CN - Cina 208
IT - Italia 175
DE - Germania 93
AR - Argentina 66
GB - Regno Unito 53
FI - Finlandia 45
BD - Bangladesh 36
UA - Ucraina 36
EC - Ecuador 34
ID - Indonesia 32
MX - Messico 31
IN - India 26
CA - Canada 25
AE - Emirati Arabi Uniti 23
CO - Colombia 21
IQ - Iraq 19
TR - Turchia 18
ZA - Sudafrica 16
AT - Austria 14
PY - Paraguay 14
PL - Polonia 12
PE - Perù 11
FR - Francia 10
UY - Uruguay 10
UZ - Uzbekistan 10
VE - Venezuela 10
NL - Olanda 9
DO - Repubblica Dominicana 8
ES - Italia 8
MA - Marocco 8
CL - Cile 7
JP - Giappone 7
PK - Pakistan 7
BE - Belgio 6
DZ - Algeria 5
EG - Egitto 5
LT - Lituania 5
SA - Arabia Saudita 5
AZ - Azerbaigian 4
OM - Oman 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
JM - Giamaica 3
MD - Moldavia 3
NP - Nepal 3
RO - Romania 3
TN - Tunisia 3
TW - Taiwan 3
AL - Albania 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
MK - Macedonia 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BZ - Belize 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
HN - Honduras 1
KI - Kiribati 1
KW - Kuwait 1
LV - Lettonia 1
LY - Libia 1
ML - Mali 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PH - Filippine 1
PR - Porto Rico 1
QA - Qatar 1
RS - Serbia 1
Totale 7.005
Salva come PNG Salva come JPEG
Città #
Dublin 1.080
Hong Kong 409
Singapore 367
Nyköping 208
Ashburn 180
Ho Chi Minh City 154
Santa Clara 150
Chandler 146
Princeton 128
Wilmington 126
Dallas 115
São Paulo 80
Hanoi 73
Munich 51
Beijing 48
The Dalles 45
Moscow 26
Helsinki 25
Des Moines 23
Belo Horizonte 22
Da Nang 20
Rio de Janeiro 20
Los Angeles 18
New York 18
Nuremberg 18
Brasília 17
London 16
Quito 16
Turku 16
Jacksonville 15
Shanghai 15
Curitiba 13
Guarulhos 13
Thái Bình 13
Brooklyn 12
Guangzhou 11
Martina Franca 11
Nanjing 11
Porto Alegre 11
Bari 10
Buenos Aires 10
Milan 10
Ninh Bình 10
Nocera Inferiore 10
Tashkent 10
Warsaw 10
Biên Hòa 9
Campinas 9
Can Tho 9
Johannesburg 9
Mexico City 9
Norwalk 9
Salvador 9
Trento 9
Chicago 8
Dhaka 8
Goiânia 8
Haiphong 8
Montevideo 8
Ribeirão Preto 8
San Francisco 8
Thái Nguyên 8
Wuhan 8
Ankara 7
Boston 7
Dearborn 7
Formosa 7
Fortaleza 7
Hortolândia 7
Itaquaquecetuba 7
Lima 7
Lấp Vò 7
Potenza 7
Canoas 6
Caxias do Sul 6
Garden City 6
Guayaquil 6
Pune 6
Recife 6
Rome 6
Seattle 6
Tokyo 6
Viamão 6
Atlanta 5
Baghdad 5
Brussels 5
Cabo Frio 5
Erbil 5
Hillsboro 5
Hải Dương 5
Jakarta 5
Joinville 5
Madrid 5
Manaus 5
Manchester 5
Ottawa 5
Phủ Lý 5
Stevenage 5
Sumaré 5
Amsterdam 4
Totale 4.168
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of HCV-Related cryoglobulinemic vasculitis: molecular, immunological and clinical analysis 145
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 97
T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. 84
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 82
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 80
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 77
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. 72
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study 70
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia 70
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 68
Epigenetics in prostate cancer: clinical implications 67
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation 66
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. 66
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test 66
Barrett's esophagus and esophageal cancer: An overview 66
Association among metabolic syndrome, inflammation, and survival in prostate cancer 66
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. 65
Androgen receptor signaling pathways as a target for breast cancer treatment 65
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. 65
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 63
Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis 62
Metabolic syndrome as a peculiar target for management of prostate cancer patients 62
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer 62
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients 61
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. 60
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents 60
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. 60
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 59
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 58
Barrett's esophagus and esophageal cancer: An overview 58
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 58
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 57
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. 57
H. pylori infection and gastric cancer: State of the art (Review) 57
Biological Evolution of Castration-resistant Prostate Cancer 57
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 57
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 56
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 56
Clinical features of neuroendocrine prostate cancer 56
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 56
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 55
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. 54
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer 54
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 54
Plasma AR and abiraterone-resistant prostate cancer 54
Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview 54
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer 54
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 52
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 52
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. 52
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 52
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. 52
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. 52
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis 52
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 51
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy 51
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 51
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. 50
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide 50
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 49
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis 49
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. 49
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone 49
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 48
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 47
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 47
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer 46
The potential use of urine cell free DNA as a marker for cancer 46
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer 46
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 45
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy 45
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer 44
High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer 44
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 44
Cell-free DNA as a diagnostic marker for cancer: Current insights 44
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 44
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 43
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 43
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 43
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. 43
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 43
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib 42
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study 42
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes 42
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 41
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 41
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 41
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 40
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. 40
Hepatitis C virus infection and mixed cryoglobulinemia 40
Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: A 15-year prospective study 40
Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme 40
Precancerous colorectal lesions (Review) 40
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer 40
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 39
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 39
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer 39
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer 39
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program 38
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. 38
Totale 5.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.467
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.467
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 2 5 0 4 4 1 3
2021/2022856 4 2 3 1 371 15 25 50 102 104 17 162
2022/20231.723 186 31 86 25 47 109 3 71 1.117 15 19 14
2023/2024222 11 19 11 19 26 77 1 21 8 7 1 21
2024/20252.162 103 68 11 30 61 257 223 100 591 206 247 265
2025/20262.496 245 458 619 1.028 142 4 0 0 0 0 0 0
Totale 7.598